Combined Immune Therapy for the Treatment of Visceral Leishmaniasis

Chronic disease caused by infections, cancer or autoimmunity can result in profound immune suppression. Immunoregulatory networks are established to prevent tissue damage caused by inflammation. Although these immune checkpoints preserve tissue function, they allow pathogens and tumors to persist, and even expand. Immune checkpoint blockade has recently been successfully employed to treat cancer. This strategy modulates immunoregulatory mechanisms to allow host immune cells to kill or control tumors. However, the utility of this approach for controlling established infections has not been extensively investigated. Here, we examined the potential of modulating glucocorticoid-induced TNF receptor-related protein (GITR) on T cells to improve anti-parasitic immunity in blood and spleen tissue from visceral leishmaniasis (VL) patients infected with Leishmania donovani. We found little effect on parasite growth or parasite-specific IFNγ production. However, this treatment reversed the improved anti-parasitic immunity achieved by IL-10 signaling blockade. Further investigations using an experimental VL model caused by infection of C57BL/6 mice with L. donovani revealed that this negative effect was prominent in the liver, dependent on parasite burden and associated with an accumulation of Th1 cells expressing high levels of KLRG-1. Nevertheless, combined anti-IL-10 and anti-GITR mAb treatment could improve anti-parasitic immunity when used with sub-optimal doses of anti-parasitic drug. However, additional studies with VL patient samples indicated that targeting GITR had no overall benefit over IL-10 signaling blockade alone at improving anti-parasitic immune responses, even with drug treatment cover. These findings identify several important factors that influence the effectiveness of immune modulation, including parasite burden, target tissue and the use of anti-parasitic drug. Critically, these results also highlight potential negative effects of combining different immune modulation strategies.

[1]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[2]  Peter D. Crompton,et al.  PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. , 2015, Cell host & microbe.

[3]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[4]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[5]  R. Kumar,et al.  Leishmania Specific CD4 T Cells Release IFNγ That Limits Parasite Replication in Patients with Visceral Leishmaniasis , 2014, PLoS neglected tropical diseases.

[6]  J. Wolchok,et al.  Immune modulation for cancer therapy , 2014, British Journal of Cancer.

[7]  Patrick T. Bunn,et al.  The Regulation of CD4+ T Cell Responses during Protozoan Infections , 2014, Front. Immunol..

[8]  P. Kaye,et al.  Tissue Requirements for Establishing Long-Term CD4+ T Cell–Mediated Immunity following Leishmania donovani Infection , 2014, The Journal of Immunology.

[9]  R. Kumar,et al.  Leishmania specific CD4 T cells release IFN-γ that limits parasite replication in patients with visceral leishmaniasis , 2014 .

[10]  Peter D. Crompton,et al.  Exposure-Dependent Control of Malaria-Induced Inflammation in Children , 2014, PLoS pathogens.

[11]  R. Kumar,et al.  Immune Regulation during Chronic Visceral Leishmaniasis , 2014, PLoS neglected tropical diseases.

[12]  Daniel Argaw,et al.  Visceral Leishmaniasis Outbreak in South Sudan 2009–2012: Epidemiological Assessment and Impact of a Multisectoral Response , 2014, PLoS neglected tropical diseases.

[13]  S. Sundar,et al.  Risk Factors for Visceral Leishmaniasis and Asymptomatic Leishmania donovani Infection in India and Nepal , 2014, PloS one.

[14]  Peter G. Smith,et al.  Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial , 2014, PLoS neglected tropical diseases.

[15]  M. Feeney,et al.  IFNγ/IL-10 Co-producing Cells Dominate the CD4 Response to Malaria in Highly Exposed Children , 2014, PLoS pathogens.

[16]  Eric W. Cross,et al.  T cell responses: naive to memory and everything in between. , 2013, Advances in physiology education.

[17]  Douglas E. Jones,et al.  Programmed Death 1–Mediated T Cell Exhaustion during Visceral Leishmaniasis Impairs Phagocyte Function , 2013, The Journal of Immunology.

[18]  P. Ascierto,et al.  Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination , 2013, Clinical Cancer Research.

[19]  S. Sundar,et al.  Leishmaniasis: an update of current pharmacotherapy , 2013, Expert opinion on pharmacotherapy.

[20]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[21]  P. Klenerman Faculty Opinions recommendation of Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. , 2012 .

[22]  E. Yang,et al.  The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets , 2011, Nature Immunology.

[23]  R. Kumar,et al.  IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. , 2011, The Journal of infectious diseases.

[24]  P. Kaye,et al.  Critical Roles for LIGHT and Its Receptors in Generating T Cell-Mediated Immunity during Leishmania donovani Infection , 2011, PLoS pathogens.

[25]  S. Stäger,et al.  Differential Regulation of the Immune Response in the Spleen and Liver of Mice Infected with Leishmania donovani , 2011, Journal of tropical medicine.

[26]  R. Kumar,et al.  IL-27 and IL-21 Are Associated with T Cell IL-10 Responses in Human Visceral Leishmaniasis , 2011, The Journal of Immunology.

[27]  S. Sundar,et al.  Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial , 2011, The Lancet.

[28]  B. Saha,et al.  CD40 Expression Levels Modulate Regulatory T Cells in Leishmania donovani Infection , 2010, The Journal of Immunology.

[29]  L. Vaickus,et al.  Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR. , 2010 .

[30]  Shyam Sundar,et al.  Single-dose liposomal amphotericin B for visceral leishmaniasis in India. , 2010, The New England journal of medicine.

[31]  V. Yardley,et al.  Therapeutic Glucocorticoid-Induced TNF Receptor-Mediated Amplification of CD4+ T Cell Responses Enhances Antiparasitic Immunity , 2010, The Journal of Immunology.

[32]  Margarida Saraiva,et al.  The regulation of IL-10 production by immune cells , 2010, Nature Reviews Immunology.

[33]  S. Henson,et al.  KLRG1—more than a marker for T cell senescence , 2009, AGE.

[34]  Jane E. Dalton,et al.  VCAM-1 and VLA-4 Modulate Dendritic Cell IL-12p40 Production in Experimental Visceral Leishmaniasis , 2008, PLoS pathogens.

[35]  D. Pellicci,et al.  Activation of Invariant NKT Cells Exacerbates Experimental Visceral Leishmaniasis , 2008, PLoS pathogens.

[36]  S. Sundar,et al.  Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis , 2007, The Journal of experimental medicine.

[37]  C. Engwerda,et al.  Balancing immunity and pathology in visceral leishmaniasis , 2007, Immunology and cell biology.

[38]  T. Nomura,et al.  Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells , 2005, The Journal of experimental medicine.

[39]  H. Murray Prevention of Relapse after Chemotherapy in a Chronic Intracellular Infection: Mechanisms in Experimental Visceral Leishmaniasis1 , 2005, The Journal of Immunology.

[40]  A. Awasthi,et al.  Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses , 2004, Nature Medicine.

[41]  P. Kaye,et al.  Immunotherapy with OX40L‐Fc or anti‐CTLA‐4 enhances local tissue responses and killing of Leishmania donovani , 2004, European journal of immunology.

[42]  S. Schultz-Cherry,et al.  Activation of TGF-β by Leishmania chagasi: Importance for Parasite Survival in Macrophages 1 , 2003, The Journal of Immunology.

[43]  D. Voehringer,et al.  Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). , 2002, Blood.

[44]  L. Abel,et al.  The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan. , 2002, Microbes and infection.

[45]  R. Coffman,et al.  Interleukin-10 (IL-10) in Experimental Visceral Leishmaniasis and IL-10 Receptor Blockade as Immunotherapy , 2002, Infection and Immunity.

[46]  C. Hunter,et al.  IL‐10 mediates susceptibility to Leishmania donovani infection , 2001, European journal of immunology.

[47]  H. Murray,et al.  Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. , 2000, The Journal of infectious diseases.

[48]  P. Kaye,et al.  Organ-specific immune responses associated with infectious disease. , 2000, Immunology today.

[49]  A. Sette,et al.  Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. , 1999, Journal of immunology.

[50]  P. Kaye,et al.  Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. , 1998, Journal of immunology.

[51]  Y. Liu,et al.  IL‐10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3‐dependent and ‐independent pathways , 1998, The EMBO journal.

[52]  K. Welte,et al.  Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. , 1987, Journal of immunology.

[53]  D. Sacks,et al.  An analysis of T cell responsiveness in Indian kala-azar. , 1987, Journal of immunology.

[54]  F. Liew,et al.  IMMUNE RESPONSE TO CHEMICALLY MODIFIED FLAGELLIN III. ENHANCED CELL-MEDIATED IMMUNITY DURING HIGH AND LOW ZONE ANTIBODY TOLERANCE TO FLAGELLIN , 1972 .

[55]  C. Parish,et al.  IMMUNE RESPONSE TO CHEMICALLY MODIFIED FLAGELLIN , 1971, The Journal of experimental medicine.

[56]  C. Hunter,et al.  Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology. , 2006, The American journal of pathology.

[57]  D. Smith,et al.  Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya. , 1982, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[58]  C. Parish Immune response to chemically modified flagellin. IV. Further studies on the relationship between humoral and cell-mediated immunity. , 1973, Cellular immunology.